Nomura Holdings Inc. cut its holdings in shares of Abbott Laboratories (NYSE:ABT) by 73.5% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 55,465 shares of the healthcare product maker’s stock after selling 153,474 shares during the quarter. Nomura Holdings Inc.’s holdings in Abbott Laboratories were worth $3,383,000 at the end of the most recent reporting period.
Other large investors have also recently bought and sold shares of the company. Rainier Group Investment Advisory LLC acquired a new position in shares of Abbott Laboratories in the 1st quarter worth approximately $114,000. FNY Investment Advisers LLC purchased a new stake in Abbott Laboratories during the 2nd quarter worth approximately $118,000. Fort L.P. purchased a new stake in Abbott Laboratories during the 2nd quarter worth approximately $119,000. Security National Bank of SO Dak increased its stake in Abbott Laboratories by 72.0% during the 2nd quarter. Security National Bank of SO Dak now owns 2,098 shares of the healthcare product maker’s stock worth $128,000 after buying an additional 878 shares during the period. Finally, Private Ocean LLC increased its stake in Abbott Laboratories by 9,868.2% during the 1st quarter. Private Ocean LLC now owns 2,193 shares of the healthcare product maker’s stock worth $131,000 after buying an additional 2,171 shares during the period. Institutional investors own 72.16% of the company’s stock.
NYSE:ABT traded up $1.23 during trading hours on Friday, reaching $69.33. 10,345,615 shares of the company’s stock were exchanged, compared to its average volume of 6,017,730. Abbott Laboratories has a 1-year low of $53.61 and a 1-year high of $74.15. The stock has a market cap of $128.70 billion, a P/E ratio of 27.73, a P/E/G ratio of 2.05 and a beta of 1.49. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.58 and a quick ratio of 1.16.
The business also recently declared a quarterly dividend, which will be paid on Thursday, November 15th. Stockholders of record on Monday, October 15th will be issued a $0.28 dividend. The ex-dividend date of this dividend is Friday, October 12th. This represents a $1.12 dividend on an annualized basis and a dividend yield of 1.62%. Abbott Laboratories’s dividend payout ratio is presently 44.80%.
In other news, insider Sharon J. Bracken sold 615 shares of Abbott Laboratories stock in a transaction dated Monday, July 30th. The shares were sold at an average price of $65.16, for a total transaction of $40,073.40. Following the completion of the sale, the insider now directly owns 40,761 shares in the company, valued at $2,655,986.76. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Brian J. Blaser sold 15,100 shares of Abbott Laboratories stock in a transaction dated Tuesday, July 24th. The stock was sold at an average price of $63.96, for a total transaction of $965,796.00. Following the sale, the executive vice president now owns 151,718 shares of the company’s stock, valued at $9,703,883.28. The disclosure for this sale can be found here. Insiders sold a total of 155,321 shares of company stock valued at $10,492,583 in the last quarter. Insiders own 0.74% of the company’s stock.
ABT has been the topic of several recent research reports. Sanford C. Bernstein assumed coverage on shares of Abbott Laboratories in a research report on Wednesday, June 27th. They issued an “outperform” rating and a $73.00 price objective on the stock. Stifel Nicolaus increased their price objective on shares of Abbott Laboratories from $71.00 to $72.00 and gave the company a “buy” rating in a research report on Thursday, July 19th. Zacks Investment Research raised shares of Abbott Laboratories from a “hold” rating to a “buy” rating and set a $70.00 target price on the stock in a research report on Thursday, July 19th. Royal Bank of Canada reaffirmed a “buy” rating and issued a $70.00 target price on shares of Abbott Laboratories in a research report on Thursday, July 19th. Finally, Wells Fargo & Co increased their target price on shares of Abbott Laboratories from $77.00 to $80.00 and gave the company an “outperform” rating in a research report on Monday, September 24th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and fifteen have given a buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $73.72.
Abbott Laboratories Profile
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. The company's Established Pharmaceutical Products segment offers branded generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptoms; gynecological disorders; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; Ménière's disease and vestibular vertigo; pain, fever, and inflammation; migraines; and anti-infective clarithromycin, as well as provides influenza vaccine and products that regulate physiological rhythm of the colon.
Further Reading: What is the NASDAQ?
Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.